
|Videos|December 16, 2022
Selecting Between Treatment With Cabazitaxel or Radiotherapy for Patients with mCRPC
Author(s)Neal Shore, MD, FACS
Dr Shore details how he approaches treatment selection between cabazitaxel and radiotherapy for patients with mCRPC.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Laura Bukavina, MD, and Gabriela Díaz, MD, on the rise of young-onset bladder cancer
3
Individualizing androgen pathway therapy in mCSPC
4
BOND-003 Cohort C: Efficacy Results
5









